12:47 , Mar 14, 2019 |  BC Innovations  |  Translation in Brief

Bacteriophages: double-edged swords

Utah researchers have shown bacteriophage-host immune interactions can trigger adverse immune responses in GI diseases, a factor phage companies may need to take into account. Phage researchers have long thought mammalian host immunity recognizes the...
13:04 , Mar 13, 2019 |  BC Innovations  |  Distillery Techniques

Gene panel to predict pain severity and identify therapies

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; plasma markers Blood expression levels of 65 genes could help predict pain severity state and identify drug compounds for pain. In blood samples from 28 patients with major psychiatric...
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
19:11 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

New bacteriophage-related therapeutic strategies for colitis and colorectal cancer

DISEASE CATEGORY: Cancer; gastrointestinal INDICATION: Colorectal cancer; colitis Patient sample and mouse studies suggest an E. coli bacteriophage cocktail could help treat bacteria-aggravated colorectal cancer and blockade of host-bacteriophage interactions via inhibition of IFNγ or...
02:34 , Feb 26, 2019 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for making iPS cells hypoimmunogenic could be used to generate allogeneic cell grafts for transplant therapies. The method involves two to three steps: simultaneous or sequential CRISPR-Cas9 (CRISPR-associated protein 9)-mediated...
20:16 , Feb 21, 2019 |  BC Innovations  |  Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
18:43 , Jan 18, 2019 |  BC Week In Review  |  Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS). ZappRx founder and CEO Zoë...
13:04 , Jan 16, 2019 |  BC Extra  |  Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS). ZappRx founder and CEO Zoë...